We’re proud to announce that our flagship probiotic strain — Lactobacillus paracasei NTU 101, marketed as Vigiis101 — has officially received GRAS (Generally Recognized As Safe) status, GRN 001232, from the U.S. Food and Drug Administration (FDA). This is the first-ever GRAS recognition for L. paracasei from Taiwan, highlighting SunWay Biotech’s excellence in R&D and our strategic vision for the global probiotic market.
The GRAS status further validates Vigiis 101’s well-established safety profile, following a comprehensive scientific review and toxicology assessment. Lactobacillus paracasei, naturally occurring in the human gut and certain dairy products, is widely known for supporting gut health, digestion, and overall wellness.
Beyond supporting a healthy gut microbiota, Vigiis 101 has demonstrated potential in scientific studies targeting atopic dermatitis, offering benefits for skin health and immune balance. As probiotics gain traction in the companion animal sector, Vigiis 101 is well-positioned to address the needs of both human and pet health markets with proven, research-backed efficacy.
👉For more information about Vigiis101:
Vigiis 101-LAB: https://lnkd.in/gE3P5JYY
Vigiis 101 for Pets: https://lnkd.in/gcamctiF
📤 Or contact us to know more:
globalservice@sunway.cc
kerry.wu@sunway.cc
